Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.41 +1.46 (+2.87%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
The drugmaker's recent dip could also be a buying opportunity. 
Via The Motley Fool
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Why Novo Nordisk Flew Almost 3% Higher on Friday
It seems to be holding off on price adjustments demanded by President Trump. 
Via The Motley Fool
Topics Government
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price target. 
Via Benzinga
This House of Representative Just Bought Up To $95K In Novo Nordisk Stock
 
Via Benzinga
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other... 
Via Benzinga
Topics Artificial Intelligence
Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India
Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market. 
Via Benzinga
3 Absurdly Cheap Stocks That Haven't Been Trading This Low in Years
These stocks are all down more than 30% this year and could prove to be bargain buys for long-term investors. 
Via The Motley Fool
Topics World Trade
Best Stock to Buy: Novo Nordisk Stock vs. UnitedHealth Stock
Healthcare stocks are underperforming this year due to unfavorable government policy. 
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
Bullishness slowly seems to be coming back to the beleaguered drugmaker. 
Via The Motley Fool
Why Eli Lilly Stock Popped Today
The GLP-1 weight loss wars have gone global. 
Via The Motley Fool
Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs. 
Via Benzinga
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly. 
Via Benzinga
The 3 Things That Matter for Viking Therapeutics Now
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases. 
Via Benzinga
Topics Lawsuit
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026. 
Via Benzinga
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock
Investors have a tough choice between these two excellent companies. 
Via The Motley Fool
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Value Investment with Undervalued Potential
NOVO-NORDISK (NVO) is a top value stock with strong fundamentals, undervalued metrics, high profitability, and steady growth in diabetes & obesity care markets. 
Via Chartmill
Novo Nordisk Stock: Buy or Sell?
News from a competitor is increasing enthusiasm for Novo Nordisk stock. 
Via The Motley Fool
Is the Market Bullish or Bearish on Novo Nordisk?
 
Via Benzinga
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
4 of the Most Undervalued Stocks in the Market Right Now
They all offer great value right now. 
Via The Motley Fool
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade
These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth. 
Via The Motley Fool
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
MarketBeat Week in Review – 08/04 - 08/08
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales 
Via MarketBeat
Topics ETFs Economy World Trade
Why Hims & Hers Stock Sank This Week
The telehealth platform is growing quickly but is in the middle of a legal battle. 
Via The Motley Fool
Topics Lawsuit
Why Novo Nordisk Stock Flew Higher on Friday
It looked good next to a company that has been stealing its thunder lately. 
Via The Motley Fool
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
Novo Nordisk Stock Investors Need to Know This
The company is using litigation to protect sales of its most popular treatments. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.